Sugi Predict

Sugi Predict / Compounds / SCHEMBL4457949

SCHEMBL4457949

SCHEMBL4457949

CC(C)Oc1c(Cl)cc(-c2cccnc2)c2cccnc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 5/20 0.43
▸ SKP2 Q13309 5/20 0.43
▸ CYP11B1 P15538 3/20 0.42
▸ HIF1A Q16665 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ MKNK1 Q9BUB5 1/20 0.40
▸ MKNK2 Q9HBH9 1/20 0.40
▸ CYP17A1 P05093 2/20 0.39
▸ CYP11B2 P19099 2/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ DYRK1B Q9Y463 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP19A1 P11511 1/20 0.39
▸ L3MBTL1 Q9Y468 3/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ JAK2 O60674 1/20 0.38
▸ MET P08581 1/20 0.38
▸ CYP2A6 P11509 1/20 0.38
▸ CCR6 P51684 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4455362 0.79 L3MBTL1 (0.53) HIF1AKDM4ECYP3A4L3MBTL1NPC1
SCHEMBL4457946 0.79 L3MBTL1 (0.47) HIF1AKDM4ECYP3A4L3MBTL1NPC1
SCHEMBL4457755 0.78 KDM4E (0.62) CKS1BSKP2CYP11B1HIF1AKDM4E
SCHEMBL13625059 0.78 CCR1 (0.47) HIF1AKDM4ECYP3A4L3MBTL1NPC1
SCHEMBL4446193 0.77 ALDH1A1 (0.49) HIF1AKDM4ECYP3A4L3MBTL1NPC1
SCHEMBL4455356 0.77 CKS1B (0.42) CKS1BSKP2HIF1AL3MBTL1NPC1
SCHEMBL13313237 0.77 S1PR1 (0.36) HIF1AKDM4ECYP3A4L3MBTL1NPC1
SCHEMBL4036442 0.76 PIK3CD (0.49) HIF1AKDM4ECYP3A4L3MBTL1NPC1
SCHEMBL16407667 0.75 L3MBTL1 (0.43) HIF1AKDM4ECYP3A4L3MBTL1NPC1
SCHEMBL16407669 0.74 CCR1 (0.41) CKS1BSKP2KDM4EL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 — — US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 — — US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 — — US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 — — US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 — — US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 — — US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 — — US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 — — US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 — — US disclosed
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-04-02 — — US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 — — US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 — — US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 — — US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 — — US disclosed
EP-1539700-A4 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LTD (AU) 2006-06-28 — — EP disclosed
US-20060089380-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LTD. (AU) 2006-04-27 — — US disclosed
CN-1681791-A 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LTD (AU) 2005-10-12 — — CN disclosed
EP-1539700-A1 8-HYDROXY QUINOLINE DERIVATIVES Prana Biotechnology Ltd (AU) 2005-06-15 — — EP disclosed
WO-2004007461-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2004-01-22 — — WO disclosed
WO-2004007461-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN CKS1B 3922/4885SKP2 2754/4885CYP11B1 126/4885
US-20080161353-A1 8-Hydroxy quinoline derivatives PARK7, COQ8A, NLN CKS1B 3922/4885SKP2 2754/4885CYP11B1 126/4885
US-20060089380-A1 8-Hydroxy quinoline derivatives PARK7, HTT, SNCA CKS1B 3051/4885SKP2 586/4885CYP11B1 211/4885
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN CKS1B 3922/4885SKP2 2754/4885CYP11B1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.